Asset profile
ALTO-203
Small molecule
Evidence outlook · lead readout
NCT06391593 · Major Depressive Disorder, Anhedonia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06391593: The study was randomized and quadruple-blind, with placebo control and 69 participants, using a crossover design for single doses and parallel groups for 28 days of dosing. Its primary efficacy measure was a pharmacodynamic mood and alertness scale rather than a hard clinical outcome, and the primary comparison cannot be judged because results are not posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.